Nilotinib Zentiva

Nilotinib, the active ingredient in Nilotinib Zentiva, is a tyrosine kinase inhibitor presented as a tablet for oral use. It selectively blocks the BCR‑ABL kinase and is indicated for treatment of Philadelphia chromosome‑positive chronic myeloid leukemia in adult patients.\n\nGNH India supplies Nilotinib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nilotinib targets the BCR‑ABL driven pathway in chronic myeloid leukemia and is used across disease phases.\n\n- Chronic phase CML: reduces leukemic cell proliferation and achieves cytogenetic response.\n- Accelerated phase CML: helps attain hematologic and molecular remission when used as monotherapy or in combination.\n- Blast phase CML: employed as part of multi‑agent regimens to suppress BCR‑ABL activity and improve survival outcomes.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.\n\nCommon Side Effects:\n- Rash or skin irritation\n- Nausea or vomiting\n- Diarrhea\n- Elevated liver enzymes\n- Fatigue or weakness\n- Muscle cramps\n\nSerious or Rare Side Effects:\n- Cardiovascular events such as arterial occlusion\n- QT interval prolongation leading to arrhythmia\n- Severe pancreatitis or hepatic failure

Nilotinib requires careful monitoring and specific precautions before and during therapy.\n\n- Dose adjustment in hepatic impairment: reduce dose based on liver function tests.\n- Monitor cardiovascular health: assess for peripheral arterial disease and ischemic events.\n- Evaluate QT interval: obtain baseline ECG and repeat periodically.\n- Avoid in patients with active severe pancreatitis: discontinue if pancreatitis develops.\n- Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Nilotinib can interact with several concomitant medicines, influencing its safety and efficacy.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce nilotinib exposure.\n- Proton pump inhibitors taken within 2 hours of nilotinib: decrease absorption.\n- Anticoagulants (e.g., warfarin): increased bleeding risk due to altered metabolism.\n\nModerate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may raise plasma levels, consider dose adjustment.\n- Statins metabolized by CYP3A4 (e.g., simvastatin): increased risk of myopathy, monitor lipid‑lowering therapy.